Patent: 10,016,440
✉ Email this page to a colleague
Summary for Patent: 10,016,440
Title: | Methods of enhancing antibody-dependent cellular cytotoxicity |
Abstract: | The application relates to method of increasing antibody-dependent cellular cytotoxicity in a subject receiving therapeutic monoclonal antibody treatment. In some embodiments, methods are provided for administering to subject to a subject in need thereof a therapeutic antibody in conjunction with an ADCC enhancer molecule. |
Inventor(s): | Hershberg; Robert (Seattle, WA) |
Assignee: | VentiRx Pharmaceuticals, Inc. (Seattle, WA) |
Application Number: | 13/092,088 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,016,440 |
Patent Claims: | see list of patent claims |
Details for Patent 10,016,440
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | November 26, 1997 | 10,016,440 | 2030-04-21 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | September 25, 1998 | 10,016,440 | 2030-04-21 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | February 10, 2017 | 10,016,440 | 2030-04-21 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | February 12, 2004 | 10,016,440 | 2030-04-21 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | March 28, 2007 | 10,016,440 | 2030-04-21 |
Amgen Inc. | VECTIBIX | panitumumab | Injection | 125147 | September 27, 2006 | 10,016,440 | 2030-04-21 |
Genentech, Inc. | RITUXAN HYCELA | rituximab and hyaluronidase human | Injection | 761064 | June 22, 2017 | 10,016,440 | 2030-04-21 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |